Toronto Dominion Bank Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Toronto Dominion Bank reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 14,592 shares of the biopharmaceutical company’s stock after selling 1,781 shares during the period. Toronto Dominion Bank’s holdings in Alnylam Pharmaceuticals were worth $1,058,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALNY. Northern Trust Corp raised its position in shares of Alnylam Pharmaceuticals by 2.1% in the second quarter. Northern Trust Corp now owns 569,883 shares of the biopharmaceutical company’s stock valued at $41,352,000 after purchasing an additional 11,578 shares during the period. Canada Pension Plan Investment Board raised its holdings in Alnylam Pharmaceuticals by 115.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 4,766 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,553 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 36,985 shares of the biopharmaceutical company’s stock worth $2,684,000 after purchasing an additional 1,680 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Alnylam Pharmaceuticals by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 400,693 shares of the biopharmaceutical company’s stock worth $29,075,000 after purchasing an additional 10,495 shares during the last quarter. Finally, Quantamental Technologies LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $130,000. Institutional investors and hedge funds own 94.20% of the company’s stock.

NASDAQ ALNY traded down $2.46 during mid-day trading on Wednesday, hitting $85.36. The company’s stock had a trading volume of 159,567 shares, compared to its average volume of 681,346. The company’s 50 day simple moving average is $80.65 and its 200 day simple moving average is $78.99. Alnylam Pharmaceuticals, Inc. has a twelve month low of $60.27 and a twelve month high of $96.14. The company has a current ratio of 6.28, a quick ratio of 6.16 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of -11.28 and a beta of 2.35.



Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The business had revenue of $38.20 million during the quarter, compared to the consensus estimate of $42.24 million. During the same quarter last year, the firm posted ($1.61) EPS. Alnylam Pharmaceuticals’s revenue was up 27.8% compared to the same quarter last year. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -8.21 EPS for the current year.

Several brokerages have recently commented on ALNY. Barclays reaffirmed a “buy” rating and set a $125.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 23rd. Cowen reduced their price objective on shares of Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Piper Jaffray Companies set a $145.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Finally, Stifel Nicolaus set a $116.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $114.69.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: Cash Asset Ratio

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.